The pharmacokinetics of buserelin after intramuscular administration in pigs and cows

Background Buserelin is a luteinizing hormone releasing hormone (LHRH) agonist used for the treatment of hormone-dependent diseases in males and females. However, the pharmacokinetics of buserelin in pigs and cows are not fully understood. This study was designed to develop a sensitive method to determine the concentration of buserelin in blood plasma and to investigate the pharmacokinetic parameters after intramuscular (i.m.) administration in pigs and cows. Results A sensitive and rapid stability method based on ultra-performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) was developed. The pharmacokinetic parameters of buserelin after i.m. administration were studied in five pigs and five cows at a single dose of 1 mg per pig and 3 mg per cow. The plasma kinetics were analyzed by WinNonlin 8.1.0 software using a non-compartmental model. The mean concentration area under the curve (AUC(0-t)) was 25.02 +/- 6.93 h x ng/mL for pigs and 5.63 +/- 1.86 h x ng/mL for cows. The maximum plasma concentration (C-max) and time to reach the maximum concentration (t(max)) were 10.99 +/- 2.04 ng/mL and 0.57 +/- 0.18 h for pigs and 2.68 +/- 0.36 ng/mL and 1.05 +/- 0.27 h for cows, respectively. The apparent volume of distribution (V-z) in pigs and cows was 80.49 +/- 43.88 L and 839.88 +/- 174.77 L, respectively. The elimination half-time (t(1/2)), and clearance (CL) were 1.29 +/- 0.40 h and 41.15 +/- 11.18 L/h for pigs and 1.13 +/- 0.3 h and 545.04 +/- 166.40 L/h for cows, respectively. No adverse effects were observed in any of the animals. Conclusion This study extends previous studies describing the pharmacokinetics of buserelin following i.m. administration in pigs and cows. Further studies investigating other factors were needed to establish therapeutic protocol in pigs and cows and to extrapolate these parameters to others economic animals.

Automated summary

A sensitive method was developed to determine the concentration of buserelin in blood plasma and investigate its pharmacokinetic parameters after intramuscular administration in pigs and cows. The study found differences in the pharmacokinetics of buserelin between pigs and cows, suggesting the need for further research to establish treatment protocols.